Ushbu ish iqtibos qilgan ishlar

378 ta ish

Ish: Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease

Hallmarks of Cancer: The Next Generation
Douglas Hanahan, Robert A. Weinberg
Sharh maqola201118 iqtibos
ABI
Targeting cancer stem cell pathways for cancer therapy
Liqun Yang, Pengfei Shi, Gaichao Zhao +8
Sharh maqola20205 iqtibos
ABI
mTOR: a pharmacologic target for autophagy regulation
Young Chul Kim, Kun‐Liang Guan
Sharh maqola20154 iqtibos
ABI
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo González, Catharina Hagerling, Zena Werb
Sharh maqola20184 iqtibos
ABI
Targeting non-coding RNAs to overcome cancer therapy resistance
Baoqing Chen, Mihnea P. Dragomir, Yang Chen +3
Sharh maqola20224 iqtibos
ABI
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Yujie Li, Qin Jiang, Guo-Fan Cao +2
Sharh maqola20153 iqtibos
ABI
The Role of mTOR Signaling as a Therapeutic Target in Cancer
N. V. Popova, Manfred Jücker
Sharh maqola20213 iqtibos
ABI
Sarlavhasiz
Boshqa3 iqtibos
ABI
Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells
M.-s. Jung, Jin Kyung Rho, Y-M Kim +7
Maqola20122 iqtibos
ABI
Rapamycin passes the torch: a new generation of mTOR inhibitors
Don Benjamin, Marco Colombi, Christoph Moroni +1
Sharh maqola20112 iqtibos
ABI
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
Anna V. Tinker, Susan Ellard, Stephen Welch +7
Maqola20132 iqtibos
ABI
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
Dos D. Sarbassov, Siraj M. Ali, Do‐Hyung Kim +5
Maqola20042 iqtibos
ABI
mTOR Signaling in Growth Control and Disease
Mathieu Laplante, David M. Sabatini
Sharh maqola20122 iqtibos
ABI
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by <i>Nanoparticle Albumin-Bound</i> –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
Diana Cirstea, Teru Hideshima, Scott J. Rodig +15
Maqola20102 iqtibos
ABI
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton, David M. Sabatini
Sharh maqola20172 iqtibos
ABI
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer
Pedro C. Barata, Matthew M. Cooney, Prateek Mendiratta +3
Maqola20182 iqtibos
ABI
Autophagy, cancer stem cells and drug resistance
Alexandra G. Smith, Kay F. Macleod
Sharh maqola20182 iqtibos
ABI
Overexpression of long noncoding RNA GAS5 suppresses tumorigenesis and development of gastric cancer by sponging miR-106a-5p through the Akt/mToR pathway
Shuaijun Dong, Xiefu Zhang, Dechun Liu
Preprint20192 iqtibos
ABI
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Jing Yang, Ji Nie, Xuelei Ma +3
Sharh maqola20192 iqtibos
ABI
The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary
S Sneha, Rohit P. Nagare, Chirukandath Sidhanth +6
Maqola20202 iqtibos
ABI
The double-edged sword of H19 lncRNA: Insights into cancer therapy
Yun Wei Shermane Lim, Xiaoqiang Xiang, Manoj Garg +4
Sharh maqola20202 iqtibos
ABI
Targeting tumor-associated macrophages to synergize tumor immunotherapy
Xiaonan Xiang, Jianguo Wang, Di Lu +1
Sharh maqola20212 iqtibos
ABI
Targeting PI3K/Akt signal transduction for cancer therapy
Yan He, Miao Sun, Guo Geng Zhang +4
Sharh maqola20212 iqtibos
ABI
mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment
Sahar Mafi, Behzad Mansoori, Shahram Taeb +4
Sharh maqola20222 iqtibos
ABI
Signaling pathways in cancer metabolism: mechanisms and therapeutic targets
Mengshu You, Zhuolin Xie, Nan Zhang +6
Sharh maqola20232 iqtibos
ABI